List of Excipients in API APROCITENTAN
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing APROCITENTAN
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Idorsia Pharmaceuticals Ltd | TRYVIO | aprocitentan | 80491-0812 | CELLULOSE, MICROCRYSTALLINE | 2029-03-22 |
| Idorsia Pharmaceuticals Ltd | TRYVIO | aprocitentan | 80491-0812 | CROSCARMELLOSE SODIUM | 2029-03-22 |
| Idorsia Pharmaceuticals Ltd | TRYVIO | aprocitentan | 80491-0812 | FERRIC OXIDE RED | 2029-03-22 |
| Idorsia Pharmaceuticals Ltd | TRYVIO | aprocitentan | 80491-0812 | FERRIC OXIDE YELLOW | 2029-03-22 |
| Idorsia Pharmaceuticals Ltd | TRYVIO | aprocitentan | 80491-0812 | FERROSOFERRIC OXIDE | 2029-03-22 |
| Idorsia Pharmaceuticals Ltd | TRYVIO | aprocitentan | 80491-0812 | HYDRATED SILICA | 2029-03-22 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for APROCITENTAN
Excipient focus: CELLULOSE, MICROCRYSTALLINE
APROCITENTAN drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Idorsia Pharmaceuticals Ltd | aprocitentan | 80491-0812 |
| >Company | >Ingredient | >NDC |
APROCITENTAN drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
APROCITENTAN drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Idorsia Pharmaceuticals Ltd | aprocitentan | 80491-0812 |
| >Company | >Ingredient | >NDC |
APROCITENTAN drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
APROCITENTAN drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Idorsia Pharmaceuticals Ltd | aprocitentan | 80491-0812 |
| >Company | >Ingredient | >NDC |
APROCITENTAN drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
APROCITENTAN drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Idorsia Pharmaceuticals Ltd | aprocitentan | 80491-0812 |
| >Company | >Ingredient | >NDC |
APROCITENTAN drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
APROCITENTAN drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Idorsia Pharmaceuticals Ltd | aprocitentan | 80491-0812 |
| >Company | >Ingredient | >NDC |
APROCITENTAN drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDRATED SILICA
APROCITENTAN drug variants containing HYDRATED SILICA
| Company | Ingredient | NDC |
|---|---|---|
| Idorsia Pharmaceuticals Ltd | aprocitentan | 80491-0812 |
| >Company | >Ingredient | >NDC |
APROCITENTAN drug variants not containing HYDRATED SILICA
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE
APROCITENTAN drug variants containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Idorsia Pharmaceuticals Ltd | aprocitentan | 80491-0812 |
| >Company | >Ingredient | >NDC |
APROCITENTAN drug variants not containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
APROCITENTAN drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Idorsia Pharmaceuticals Ltd | aprocitentan | 80491-0812 |
| >Company | >Ingredient | >NDC |
APROCITENTAN drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
APROCITENTAN drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Idorsia Pharmaceuticals Ltd | aprocitentan | 80491-0812 |
| >Company | >Ingredient | >NDC |
APROCITENTAN drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
APROCITENTAN drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Idorsia Pharmaceuticals Ltd | aprocitentan | 80491-0812 |
| >Company | >Ingredient | >NDC |
APROCITENTAN drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
APROCITENTAN drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Idorsia Pharmaceuticals Ltd | aprocitentan | 80491-0812 |
| >Company | >Ingredient | >NDC |
APROCITENTAN drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
APROCITENTAN drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Idorsia Pharmaceuticals Ltd | aprocitentan | 80491-0812 |
| >Company | >Ingredient | >NDC |
APROCITENTAN drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TRIETHYL CITRATE
APROCITENTAN drug variants containing TRIETHYL CITRATE
| Company | Ingredient | NDC |
|---|---|---|
| Idorsia Pharmaceuticals Ltd | aprocitentan | 80491-0812 |
| >Company | >Ingredient | >NDC |
APROCITENTAN drug variants not containing TRIETHYL CITRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
